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There is little doubt that the specific immune response is under direct genetic con- 
trol at  several levels (1).  However,  the  extent to which  environmental factors can 
modify regulation of the immune response is not well defined. The microbial flora of 
an animal certainly represents the most pervasive source of environmental influence; 
but the effect which bacteria may exert on the immune capacity, other than adjuvant 
properties, has received little attention. We propose that products of bacteria such as 
Group A  streptococci, which  are so common in  the human  environment, can  have 
considerable qualitative and quantitative influence on the immune response. 
In a preliminary report (2) we described a cytoplasmic component in extracts 
of  mechanically  disrupted  Group  A  streptococci  which  suppresses  the  anti- 
body response of mice against sheep red blood cells (SRBC)3 This component 
exists in  a  very polydisperse complex with  activity distributed over a  broad 
size  range  which  can  be  partially  resolved  by  Sepharose  chromatography. 
This paper describes the  distribution of this material as it occurs in extracts 
of  Group  A  streptococci processed  in  magnesium-free  phosphate  buffer  and 
defines some  of  the  parameters  of  its immunosuppressive  effect  on  the  host. 
The buffer composition is important insofar as it affects stability of ribosomes 
and aggregation. A  subsequent paper  2 will demonstrate  that under  conditions 
of  maximum  ribosome  stability the  immunosuppressant  factor  is  associated 
with  ribosomes and  can  be  derived from  these  structures  as  a  low molecular 
weight protein. 
Materials and Methods 
Animals.--An outbred strain of Swiss-Webster mice from Carworth Farms, N. Y., and a 
closed colony bred for 20 yr at the University of North Carolina School of Public Health 
(Chapel Hill, N. C.) were used. 
* This work was supported in part by grant AIJ~0949 from the U. S. Public Health Service. 
:~ Present address: Department of Bacteriology,  American University, Beirut, Lebanon. 
1  Abbreviations used in this paper: PBS, phosphate-buffered  saline;  PFC, plaque-forming 
cells; SF, Sepharose fractions;  SRBC, sheep red blood cells. 
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Bacterial Cultures and Fractions.--Group  A, Type  3,  strain D-58  streptococci were cul- 
tured for 18 hr at 37°C in Difco Todd-Hewitt broth (Difco Labs., Detroit, Mich.). Cells were 
collected by continuous flow centrifugation at  12,000  rpm in a  Sorvail centrifuge (Ivan Sor- 
vall, Inc., Norwalk, Conn.), washed three times with cold saline, and resuspended in 0.05 
sodium phosphate buffer pH  7.2 plus 0.1 g  NaC1 to a  concentration of 350 Klett units in a 
Klett-Summerson colorimeter (Klett Mfg. Co., New York) with a No. 54 green filter. This sus- 
pension was disrupted in a Braun shaker (Bronwill Scientific Inc.,  Rochester, N.Y.) for 3 min, 
using No. 12 glass beads and l  drop of tributyl phosphate to prevent foaming. After settling 
of the glass beads, the supernate and washings of the glass beads were pooled and diluted with 
cold buffer to reduce viscosity. This suspension was then centrifuged at  12,000  g for 30 min 
to separate cell wall material  (12p30)  and the supernate centrifuged two successive times at 
37,000  g  for  45  min  to  remove  remaining cell wall  fragments  and  the  large  aggregates 
(37p45). The supernate  (37s45)  was the crude phosphate-buffered  saline (PBS)  extract, and 
some of  this was further centrifuged at 100,000  g for 60 rain to yield the 100s60 extract used 
in some experiments.  Each  of  these  sediments  and supernates was dialyzed against water 
and lyophilized. 
Measurement of Antibody-Forming  Cells.--The  hemolytic plaque technique of  Jerne and 
Nordin (3) was used to detect direct plaque-forming cells (PFC) which we assume to be pro- 
ducing "/M or 19S antibody. The indirect plaque technique developed by Sterzl and l~iha (4) 
was used to detect "/G or 7S antibody-forming cells.  The facilitating antibody was made by 
immunizing rabbits with mouse globulin eluted from a diethylaminoethyl (DEAE)-cellulose 
column with 0.005 ~  tris (hydroxymethyl) aminomethane (Tris) buffer pH 8.4. The optimum 
dilution of this antiserum was 1/150. At this dilution the antiserum inhibited 50% of the "I'M 
PFC. This factor was used to calculate the net 3'G PFC. 
Mice were immunized intraperitoneally with 4  X  l0  s SRBC and hemolytic PFC measured 
in spleen cell stlspension were  collected 4  days later,  unless otherwise specified.  Duplicate 
measurements of PFC were done on spleen cell suspensions of each individual mouse. 
Sepharose 2B  Gel  Filtratlon.--Ascending  chromatography  was  done  on  Sepharose  2B 
(Pharmacia Fine Chemicals Inc., Piscataway,  N.  J.)  in a  95  X  2.5  cm column. 300 mg of 
37s45 were applied to the column and fractions were eluted with 0.15 g  NaC1 at a  rate of 10 
ml/hr. Aseptic technique was carefully observed. 
Analysis  of Data.--Statisticat  calculations were done in the University of North Carolina 
Computer Center  (Chapel Hill,  N.  C.)  and probability of differences obtained by one-way 
analysis of variance. 
RESULTS 
Effect of Interval, Number of Injections,  and  Total Dose of Crude PBS Extract 
on  Immunosuppressive  Action.-- 
Four groups of mice were injected intraperitoneally with crude PBS extract  (100s60)  as 
follows: group I  received one injection of 5.0 mg immediately before SRBC; group II was 
given six  injections of 2.5 mg each, every other day and SRBC injected with the last dose; 
group III was given 13 injections every other day and SRBC with the last dose; group IV 
was the same as group III except the SRBC was given 7 days after the last (13th) injection. 
A  control group given the same schedule of injections of saline was included with each ex- 
perimental group. Direct PFC were determined 4 days after the injection of SRBC. 
Table I  shows  that  1,  6,  or  13  injections produced  approximately  the  same 
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injection.  No  suppression  was  obtained,  however,  after  13  injections  if  the 
interval between the last injection and SRBC was extended to 7 days. 
~.  In another experiment, groups of 10 mice were given a single injection of 5.0 
mg of 100s60 at intervals of 1 or 2 days after SRBC or 1, 2, 7, or 14 days before 
SRBC.  Highest suppression was obtained with an interval of 1  day  (30%  of 
control, P  =  0.007)  or 2  days  (43%  of control, P  =  0.01)  before SRBC. No 
significant suppression was observed at the other intervals. Comparable results 
TABLE I 
Effect of Interval, Number of Injections, and Total Dose of Crude PBS Extract on Primary 
Immune Response 
Total  No.  %  of 
Group*  100s60  mg spleen/g:~  PFC/106 cells:~  Control 
injected  mice 
I  100s60  X  1 
Control 
P§ 
II  100s60 ×  6 
Control 
P 
mg  % 
5  7  4.74  4-  0.87  128  4-  80  40 
7  5.43  ±  0.63  317  4-  153 
0.12  0.01 
15  10  5.5  4-  1.16  125  -4-  106  39 
10  5.5  4-  1.54  317  4-  192 
0.98  0.01 
III lOOs60 x  13 
Control 
P 
32.5  5  7.52  4-  3.8  41  4- 42  44 
5  4.89  4-  1.1  183  +  60 
0.18  0.01 
IV  100s60 ×  13 (7 day) 
Control 
P 
32.5  5  5.7  -4-  1.0  391  +  176  72 
5  6.5  4-  1.1  546  4-  266 
0.28  0.31 
* For details, see text. 
Mean 4-1 so. 
§ Probability calculated by one-way analysis of variance. 
were obtained with a  Sepharose fraction, although fewer intervals were studied 
(see below). 
Filtration  of  Crude  PBS  Extracts  of Group  A  Streptococci  on  Sepharose.-- 
The immunosuppressive activity occurs in crude PBS extracts as a  large com- 
plex distributed over a  broad spectrum of aggregate sizes. Comparison of frac- 
tions derived by differential centrifugation shows that most of the activity is 
in  the  supernatant  at  100,000  g,  although  some  is  sedimentable at  this  and 
lower forces. Activity soluble at 37,000  g  is not  retained by Sephadex  G-200 
(Pharmacia Fine Chemicals, Inc.) and is retained by an Amicon XM-100 mem- 
brane  (Amicon Corp., Lexington, Mass.). This soluble crude extract was sep- 
arated into  several fractions by filtration on  Sepharose 2B  (Fig.  1).  Each  of 1256  IMMUNOSUPPRESSANT  FROM  GROUP  A  STREPTOCOCCI 
these  Sepharose  fractions  (SF)  is  obviously heterogeneous and  shows two to 
three  precipitin  lines  in  immunodiffusion.  Assay  for  immunosuppression  re- 
vealed that activity is associated with the entire range of molecular sizes repre- 
sented in these fractions (Fig.  2).  Nevertheless,  a  considerable increase in ac- 
tivity on a dry weight basis was achieved when compared with the initial crude 
extract  (37s45).  40%  of  the  material  placed  on  the  column was  recovered. 
Fraction II (SF-II)  contained the  greatest  total  activity,  considering that  it 
had  the  bulk  of  recovered  eluate  (27%).  Titration  of  SF-II showed  a  dose 
effect on the primary immune response to SRBC (Table II). 
The effect of the interval of injection between SF-II and SRBC is shown in 
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FIGURE 1.  Ascending chromatography  of PBS extract (37s45) on Sepharose 2B. 300 mg 
sample eluted with 0.15 M  NaC1 at flow rate of 10 ml/hr. 
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1 day before SRBC. Less effect,  although still  significant, is observed with an 
interval of 7 days before SRBC. When SF-II is injected 1 day after SRBC the 
response  to  SRBC  is  enhanced,  although  the  difference  is  of  low  statistical 
significance. 
Suppression by SF-II of Indirect  and  Direct PFC in the Primary and Sec- 
ondary  Immune  Response.--To  determine  if  SF-II delays  rather  than  sup- 
presses  the primary immune response,  PFC  were measured in  the  spleens  of 
mice injected with 1 mg of SF-II 24 hr before SRBC. Both direct and indirect 
PFC  were determined 8  days after  SRBC  (Table  IV). The direct  PFC  were 
very low at this time interval which limits reliability, but about 50 % suppres- 
sion was obtained, while  the net indirect PFC were reduced 85 ~. 
To determine  the  effect of SF-II on the secondary response, mice were  in- 
jected with  1 mg of SF-II 24 hr before the second dose of SRBC, which was ARTIN  It.  MALAKIAN  AND  ]'OLIN tI.  SCEWAB  1257 
injected 21  days after the primary immunization.  No SF-II was given before 
the first injection of SRBC.  Direct and indirect PFC  were measured at both 
2  and 4  days after the second injection of SRBC.  As shown  in Table V, the 
direct PFC  per spleen were reduced significantly on day 4  (P  =  0.007)  and 
the net indirect PFC per spleen were reduced 79 %  on day 2  (P  =  0.004)  and 
80% on day 4  (P  =  0.002). 
To determine  the  effect of SF-II on  development of memory cells during 
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FIGURE  2.  Suppression of primary immune response with fractions of PBS extract (37s45) 
obtained by Sepharose chromatography. Each group was injected with 5.0 mg  (lyophilized 
weight) intraperitoneaUy. Each point represents one mouse. Because of the large number of 
mice, each group was assayed on a different day and a control group (injected with saline) was 
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TABLE  II 
Effect  of Dose of SF-II on Primary Immune Response  to SRBC 
% of 
Group  Dose SF-II  No. mice  PFC/spleen >( 10  4  Control  /~ 
/~g  % 
I  SF-II  200  7  6.0  4-  9.8  33  0.02 
Saline  --  8  18.0  4-  8.9 
II  SF-II  400  4  0.77  4-  0.48  6  0.001 
Saline  --  5  13.6  4-  4.3 
III  SF-II  1000  8  0.52  4-  0.3  2  0.0001 
Saline  --  6  22.8  4-  9.4 
TABLE  III 
Effect of Interval  between SF-H and SRBC 
% of 
No.  PFC/spleen X 104  Control  P  Group  Interval  mice 
% 
I  SF-II  1 day after SRBC  7  28.2  4-  19.3  180  0.12 
Contro[  7  15.6  4-  5.3 
II  SF-II  1 day before SRBC*  8  0.52  4-  0.3  2  0.0001 
Control  6  22.8  4-  9.4 
IIl  SF-II  7 days before SRBC  8  7.3  4-  4.8  28  0.0004 
Control  8  25.7  ±  9.4 
* Same as group III in Table II. 
TABLE  IV 
Effect of SF-I1 on Direct and Indirect PFC in the Primary Response  at 8 days  after SRBC 
No.  Cells/ 
Group  mice  spleen  X 108 
PFC/spleen X 103 
Direct  Indirect  Net indirect~ 
Experimen-  8  2.7  ±  0.57  6.6  4-  8.2  10.4  4-  7.3  7.7  4-  4.8 
tal* 
Control  7  2.5  4-  0.24  13.3  4-  7.1  55.9  4-  15.7  50.9  4-  14.6 
P  0.52  0.1  0.0001  0. 0001 
* Mice were injected i.p. with 1.0 mg SF in saline 24 hr before 4  X  108 SRBC i.p,  Spleen 
cells  were collected  8 days after SRBC.  Controls received saline and SRBC. 
:~ Corrected for 50% inhibition of 7M by anti-IgG serum. ARTIN  H.  MALAKIAN AND  JOHN  H.  SCHWAB  1259 
the primary  immune  response,  1  mg  of  SF-II was  injected 1  day  before the 
first injection of SRBC and a  second injection of SRBC was given 3  wk later. 
SF-II was  given  only before the  first  SRBC.  Direct  and  indirect  PFC  were 
measured 2  days after the second injection of SRBC.  In spite of the high sup- 
TABLE  V 














No.  Cells/ 
mice  spleen  X 108 
2.95  -4-  0.57 
2.20  4-  0.32 
0.02 
2.29  4-  2.9 
1.85  4-  5.0 
0.05 
PFC/spleen X  103 
Direct 
14.3  4-  12.8 
17.7  4-  7.8 
0.6 
4.3  4-  1.8 
14.1  4-  8.5 
0.007 
Indirect  Net indirect 
24.2  -4-  12.8i18.5  4-  7.6 
70.8  ±  31.£  63.6  +  29.G 
0.007  0.004  i 
224  4-  19.619.7  4-  18.  
101.3  4-  53  7  4-  52t 
I  0001  i  0.002 
* Two injections of 4  X  10  s SRBC were given i.p. 21  days apart.  1 mg SF was injected 
i.p. 24 hr before the second dose of SRBC only. Spleen cells were collected for PFC measure- 
ment at 2 or 4 days after the last SRB C. 
TABLE  VI 
Effect  of SF-II on Direct and Indirect  PFC in Secondary  Immune Response  when SF-II is 
Given Only before the First Dose of SRBC (Effect  on Immunological  Memory) 
No.  Cells/spleen  X l0  s  Group  mice 
PFC/spleen X 103 
Direct  Indirect  Net indirect 
Experimental  7  2.01  -4-  0.27  14.5  -4-  6.7  158  -4-  68  152  4-  67 
Control  6  2.05  4-  0.26  9.5  4-  5.0  122  -4-  77  118  4-  75 
P  0.80  0.16  0.62  0.58 
TABLE  VII 
Effect of SF-II on Background  PFC 
No.  mg spleen/g  mg thymus/g  Cells/spleen X  l0  s  PFC/spleen  Group  mice 
Experimental*  8  6.3  ±  2.7  2.7  4-  0.7  2.9  4-  0.57  554  4-  362 
Control  8  4.9  -4-  1.8  3.8  -4-  0.9  2.3  4-  0.75  59  -4-  51 
p  0.23  0.15  0.100  0.002 
*  1  mg SF-II injected i.p. 5 days before collection of spleen cells. Control group received 
saline. No SRBC given to either group. 1260  IMMUNOSUPPRESSANT  FROM  GROUP  A  STREPTOCCOCI 
pression of the primary response achieved with this dose of SF-II, and in con- 
trast to the suppression of the secondary response when SF-II was given only 
before the second dose of SRBC, there was a slight increase in both direct and 
indirect  PFC  in  the  secondary  response  if  SF-II was  given only  before  the 
primary immunization (Table VI). 
Effect  of SF-H  on  the  Background  PFC in  Hemolytic  Plaque  Test.--Most 
mammalian spleen cell suspensions produce a background of 19S PFC in direct 
hemolytic plaque  tests without  previous  immunization  with  SRBC  or  other 
red blood cells.  Spleens from unimmunized mice usually produce about 50-100 
plaques when sheep erythrocytes are used in the test  (5). To study the effect 
of  SF-II on  the  background  count,  1 nag  of  SF-II was  injected  into  adult 
mice and the spleen cell  suspensions were prepared 5 days later.  Control mice 
TABLE  VIII 
l"~ffect of Intravenous Injection of SF-II on Primary Immune Response 
Group  miceN°"  mg spleen/g  mg thymus/g  spleenCells/x  10  8  PFC/spleen )~  10~ 
Experimental*  6  9.98  -4-  1.84  2.88  4.  0.75  33.8  4-  25.1  24.7  4-  28.2 
Control  5  5.98  ±  0.87  3.24  4.  1.05  2.8  4.  0.73  134.0 ±  37.9 
P  0.00026  0.58  0.022  0.0006 
* 1 mg SF-II was injected  i.v.  24 hr before i.p.  injection  of 4  X  10 s SRBC.  PFC  deter- 
mined 4  days after SRBC  injection. 
were injected with saline. No SRBC were injected in either group. Table VII 
shows that SF-II produced a  10-fold increase of background counts. 
Effect  of Intravenous  Injection of SF-II on the Primary Immune Response.- 
In all previous experiments both SF-II and sheep erythrocytes were injected 
intraperitoneally. To determine whether the effect of SF-II is altered by route 
of injection,  1 mg of SF-II was injected intravenously 24 hr before the intra- 
peritoneal injection  of red  cells.  The spleen cell suspensions were prepared 4 
days after the injection of the antigen.  As shown in Table VIII, intravenous 
injection of SF-II produced very significant suppression of the 19S PFC. 
Effect  of Enzyme  Treatment  of SF-//.--SF-II  (1  mg/ml)  in Tris buffer pH 
7.2 was treated with pancreatic ribonuclease (Worthington Biochemical Corp., 
FreehoLd,  N. J.; 20 ~g/ml) for 16 hr at 37°C with a drop of chloroform added. 
A control sample was incubated without added ribonuclease. One-half of each 
sample  was  dialyzed  against  Tris  buffer.  There  was  a  large  decrease  in  ab- 
sorbance at 260 m/~ in both  the  test and control  dialyzed samples, reflecting 
considerable endogenous ribonuclease.  Each  of the four samples was injected 
into mice 24 hr before SRBC in amounts corresponding to 400 ~g of untreated ARTIN  tI.  MALAKIAN  AND  JOHN  H.  SCHWAB  1261 
SF-II. Control mice received Tris buffer. There was approximately a 95 %  re- 
duction  of  19S  PFC/spleen  produced with  all  samples  except  the  enzyme- 
treated but not dialyzed material, which contained nucleotide digest products 
known to enhance the immune response and hence would counteract the sup- 
pressant effect (Fig. 3). A  sample of the ribonuclease-treated SF-II was sub- 
sequently treated with trypsin (20 ~g/ml Tris buffer pH 8.2) for 9 hr at 37°C 
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FIGuI~  3.  Effect  of  ribonuclease  and  trypsin  on  immunosuppressant activity  of  SF-II. 
Each point  represents one mouse. SF-II  was incubated with enzyme and dialyzed,  as indi- 
cated.  Each preparation was then injected into mice 24 hr before SRBC and PFC  measured 
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and  dialyzed  against  saline.  This  treatment  destroyed most  of the  immuno- 
suppressive  activity  (Fig.  3).  Similar  experiments  demonstrated  that pronase 
also destroyed the activity, and deoxyribonuclease had no effect. 
Effect of SF-II on Immune Response to a Protein Antigen.--500  pg of SF-II 
were injected 1 day before 100 #g of heat-aggregated human ~-globulin. Serum 
was collected 8 days later and antibody measured by passive hemagglutination 
titration.  The mean  antibody  titer  of the  SF-II-treated mice was  four wells 
lower than the control group (Table IX). 
TABLE IX 
Effect of SF on Antibody Response to Aggregated Human "y-Globulin (HGG) 
Group*  No. mice  Log~ titer:~  Range 
HGG +  saline  5  7.5  2-16 
HGG +  SF  5  3.2  0-8 
* 500 #g SF and 100 #g HGG in saline injected i.p. 
Mean passive hemagglutination  titer of serum 8 days after injection of HGG. 
DISCUSSION 
Of  all  potential  sources  of  immunoregulatory  factors  in  our  environment, 
bacteria  are  the  most  ubiquitous  and  have  the  most  intimacy  with  animal 
tissues.  The Group A  streptococcus is probably the most common pathogenic 
bacterium for man, but there is no d6ubt that products of other microorganisms 
can  also  influence  immunity,  as  indicated  by recent  reports  in  the  literature 
(6-8). 
The consequences to the host of this microbial source of immunosuppressive 
agents are difficult to ascertain. The importance of timing of suppressant factor 
injection  relative  to  antigen,  which  can  determine  either  suppression  or  en- 
hancement of immunity also is  observed with  other  agents  such as 6-MP  (9) 
or endotoxin  (8).  This  complicates interpretation  of the role of microbial  im- 
munosuppressants  in host responses  to infection,  or possibly establishment  of 
a neoplastic cell  (10). 
The  immunosuppressive  factor  exists  in  PBS  extracts  of mechanically  or 
osmotically disrupted  Group A  streptococcal cells  as a  polydisperse  complex 
with  activity  distributed  over  a  broad  size  range.  After  chromatography on 
Sepharose  2B,  activity is  distributed  over the  entire  range  of molecular  sizes 
and the fractions are still very heterogeneous. This is nevertheless a very useful 
step since i  t provides material with about a 10-fold increase in potency over the 
crude  extract  and with considerably more consistency between  batches.  This 
is because  of the  separation  from  adjuvant  factors  such  as  ribonucleotides 
(11)  or cell wall mucopeptides  (12),  which  could counterbalance  an immuno- ARTIN  I-I.  MALAKIAN  AND  JOIIN  tI.  SCHWAB  1263 
suppressive effect. Thus the Sepharose filtration provides a method for obtain- 
ing reasonable amounts of material and has enabled us to investigate various 
parameters of its activity. The protein nature of the factor is indicated by its 
susceptibility to trypsin and resistance to ribonuclease and deoxyribonuclease. 
Further  characterization  of  the  active  component  and  identification  of  its 
source in the bacterial cell is described in a subsequent paper, which also dem- 
onstrates  the  resolution of  adjuvant  and  suppressive  fractions in  the  crude 
extract3 
A  single injection of the crude PBS extract (37s60  or 100s60)  1 day before 
SRBC  produced a  significant suppression of antibody-forming cells  (35%  of 
control, P  =  0.01). This was about the maximum degree of suppression which 
could be achieved with  crude material,  since higher doses or repeated injec- 
tions did not produce a greater effect. In contrast, fraction SF-II obtained by 
Sepharose filtration produced 94%  suppression with  as little as 400/~g.  We 
conclude that the maximum limit of suppression obtainable with crude mate- 
rial reflects a balance with the competing adjuvant factors. The fact that re- 
peated injection does not decrease  the  degree of suppression  obtainable  with 
crude extract suggests that SF is not immunogenic in mice and therefore prob- 
ably not functioning by antigenic competition. 
Repeated injections of crude extract do not prolong the period of immuno- 
suppression. After either single or multiple injections the immunosuppressive 
effect is lost when the  interval before SRBC  is  extended to  7 days.  On  the 
other hand,  after one  injection of  SF-II  significant  suppression  is  observed 
even with an interval of 7 days before SRBC. 
The observation that the route of injection of SF is not important shows that 
it is not functioning by influencing antigen translocation from the peritoneum 
as reported to be the effect of phytohemagglutinin in mice (13). A feature which 
distinguishes this streptoccccal factor from most other immunosuppressants is 
its  very low  toxicity. Even  repeated  large  doses induce  no  clinically visible 
effect, although the histology of the bone marrow is modified? 
The background  PFC  in  normal  mouse  spleen  reflects immunocompetent 
cells  stimulated  by  antigens  in  the  environment cross-reactive with  SRBC. 
The increase of this background level by SF reflects increased proliferation of 
these sensitized cells, and the observation that injection of SF 1 or 2 days after 
SRBC  increases the number of PFC,  is an analogous situation. The increase 
of background PFC does not indicate a cross-reactive antigen between SF and 
SRBC since no secondary response is noted when SRBC are injected at inter- 
vals up to 3 wk after SF, and addition of SF in vitro to spleen cell suspensions 
or the plating media in the PFC measurement does not reduce the development 
of hemolytic plaques. 
The mechanism by which SF suppresses antibody formation is still conjec- 
tural.  It  cannot interfere with  the  late processes of induction or production 1264  IMMUNOSUPPRESSANT  FROM  GROUP  A  STREPTOCOCCI 
since injection 1 or 2 days after antigen is ineffective and may even be stimu- 
latory. It does effect stimulation of immunocompetent cells to 7M or 7G anti- 
body production in either a primary or secondary response, but does not alter 
induction of memory cells.  Antibody formation against SRBC in mice requires 
both thymus and  bone marrow cells.  In this concept of two-cell interaction, 
the  induction  of memory is  thought  to  be  from thymus  cells  (14,  15).  This 
suggests that the site of SF action is the prethymus or bone marrow cell,  and 
current studies on lymphocyte populations of the mouse demonstrate that the 
streptococcal  immunosuppressant  is  selectively  blocking  bone  marrow  stem 
cell development? 
SUMMARY 
A component in extracts of Group A streptococci suppresses antibody forma- 
tion  in  mice  against  heterologous  erythrocyte  and  protein  antigens.  Large 
doses  are  not  toxic  and  repeated  injection  does  not  change  its  effectiveness. 
It is most effective when injected 1 or 2 days before antigen and it is not sup- 
pressive when  given after antigen.  The  active factor occurs  as  a  large poly- 
disperse  complex  and  activity  can  be  increased  10-  to  25-fold  by filtration 
through Sepharose 2B. Both direct  (3~M) and indirect  (3'G) antibody-forming 
cells  are  suppressed  in  primary and  secondary  responses.  Injection  before  a 
primary response does not reduce memory cell development. It increases rather 
than depresses the "background" antibody-forming cells to sheep erythrocytes, 
and  is  equally  effective if  injected  intraperitoneally  or  intravenously.  Ribo- 
nuclease  increases  activity  while  deoxyribonuclease  has  no  effect.  Proteases 
destroy immunosuppressive actien. 
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